IP Library Granted Patent US 9,249,403
Granted Patent B2
US 9,249,403 · App. 14/579,980 · Granted Feb 2, 2016

Polypeptides with xylanase activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,249,403
App. No.
14/579,980
Granted
Feb 2, 2016
Kind
B2
Abstract

The present invention relates to polypeptides with xylanase activity and uses thereof. The present invention also relates to method of modifying polypeptides with xylanase activity to affect, preferably to increase, xylanase activity and/or bran solubility.

Claims (23)

1. A recombinant polypeptide having xylanase activity and comprising an amino acid sequence, said amino acid sequence having at least 85% identity with SEQ ID No. 2 and an amino acid substitution in position 110, with any one different amino acid residue selected from the group consisting of:

asparagine (N), glutamic acid (E), tryptophan (W), alanine (A) and cysteine (C), wherein said position 110 is determined as the position within said polypeptide that corresponds to position 110 of B. subtilis xylanase sequence shown as SEQ ID No. 1 by alignment.

2. A recombinant polypeptide having xylanase activity and comprising an amino acid sequence, said amino acid sequence having at least 85% identity with SEQ ID No. 3 and an amino acid substitution in position 110, with any one different amino acid residue selected from the group consisting of:

asparagine (N), glutamic acid (E), tryptophan (W), alanine (A) and cysteine (C), wherein said position 110 is determined as the position within said polypeptide that corresponds to position 110 of B. subtilis xylanase sequence shown as SEQ ID No. 1 by alignment.

3. The recombinant polypeptide according claim 1 , wherein said polypeptide has at least 90% identity with SEQ ID No. 2.

4. The recombinant polypeptide according claim 2 , wherein said polypeptide has at least 90% identity with SEQ ID No. 3.

5. The recombinant polypeptide according to claim 1 , having a β-jelly roll fold.

6. The recombinant polypeptide according to claim 1 , wherein the amino acid substitution in position 110 is a substitution to alanine.

7. The recombinant polypeptide according to claim 1 , comprising one or more modification(s) at any one or more of amino acid positions: 11, 12, 13, 34, 54, 77, 81, 99, 104, 113, 114, 118, 122, 141, 154, 159, 162, 164, 166 and 175, the position(s) being determined as the corresponding position of B. subtilis amino acid sequence shown as SEQ ID No. 1.

8. The recombinant polypeptide according claim 1 , comprising one or more amino acid substitutions selected from the group consisting of: 11F, 12F, 122D, 113A, 13Y, 54Q, 54W, 113D, 141Q, 175L, 122F, 34K, 99Y, 104W, 154R, 159D, 175K, 81I , 166F, 162E, 162D, 164F, 114D, 114Y, 114F, 118V, 175K, 77L, 77M, 77S, 77V, and 77Y, the position(s) being determined as the corresponding position of B. subtilis amino acid sequence shown as SEQ ID No. 1.

9. A method of preparing a recombinant polypeptide according to claim 1 , said method comprising expressing a nucleotide sequence encoding said polypeptide; and optionally isolating and/or purifying the polypeptide after expression.

10. A nucleotide sequence encoding a recombinant polypeptide according to claim 1 .

11. A composition comprising a recombinant polypeptide prepared according to claim 9 admixed with a non-toxic component.

12. A composition comprising the nucleotide sequence according to claim 10 admixed with a non-toxic component.

13. The recombinant polypeptide of claim 3 , wherein said polypeptide has at least 95% identity with SEQ ID No. 2.

14. The recombinant polypeptide of claim 4 , wherein said polypeptide has at least 95% identity with SEQ ID No. 3.

15. The recombinant polypeptide according to claim 2 , wherein the amino acid substitution in position 110 is a substitution to alanine.

16. The recombinant polypeptide according to claim 2 , comprising one or more modification(s) at any one or more of amino acid positions: 11, 12, 13, 34, 54, 77, 81, 99, 104, 113, 114, 118, 122, 141, 154, 159, 162, 164, 166 and 175, the position(s) being determined as the corresponding position of B. subtilis amino acid sequence shown as SEQ ID No. 1.

17. The recombinant polypeptide according claim 2 , comprising one or more amino acid substitutions selected from the group consisting of: 11F, 12F, 122D, 113A, 13Y, 54Q, 54W, 113D, 141Q, 175L, 122F, 34K, 99Y, 104W, 154R, 159D, 175K, 81I, 166F, 162E, 162D, 164F, 114D, 114Y, 114F, 118V, 175K, 77L, 77M, 77S, 77V, and 77Y, the position(s) being determined as the corresponding position of B. subtilis amino acid sequence shown as SEQ ID No. 1.

18. A method of preparing a recombinant polypeptide according to claim 2 , said method comprising expressing a nucleotide sequence encoding said polypeptide; and optionally isolating and/or purifying the polypeptide after expression.

19. A nucleotide sequence encoding a recombinant polypeptide according to claim 2 .

20. A composition comprising a recombinant polypeptide prepared according to claim 18 admixed with a non-toxic component.

21. A composition comprising the nucleotide sequence according to claim 19 admixed with a non-toxic component.

Assignments (1)
CHANGE OF NAME Recorded Feb 6, 2024
From: DUPONT NUTRITION BIOSCIENCES APS
To: INTERNATIONAL N&H DENMARK APS
Reel/Frame 066494/0814 →